NextCure (NASDAQ:NXTC – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday, Wall Street Zen reports.
Other research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating on shares of NextCure in a research note on Thursday, August 13th. Weiss Ratings raised NextCure from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, November 10th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, NextCure currently has a consensus rating of “Hold” and a consensus target price of $20.00.
Check Out Our Latest Research Report on NXTC
NextCure Stock Down 4.9%
NextCure (NASDAQ:NXTC – Get Free Report) last issued its quarterly earnings results on Tuesday, November 10th. The company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($0.90) by ($0.39).
Insider Transactions at NextCure
In related news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of NextCure stock in a transaction on Friday, October 23rd. The shares were bought at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the acquisition, the insider owned 728,045 shares in the company, valued at approximately $3,516,457.35. The trade was a 0.78% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders have acquired 15,537 shares of company stock valued at $77,603. Insiders own 11.90% of the company’s stock.
Institutional Investors Weigh In On NextCure
A hedge fund recently bought a new position in NextCure stock. Soleus Capital Management L.P. acquired a new position in NextCure, Inc. (NASDAQ:NXTC – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 90,000 shares of the company’s stock, valued at approximately $451,000. Soleus Capital Management L.P. owned approximately 1.97% of NextCure as of its most recent SEC filing. 42.65% of the stock is currently owned by hedge funds and other institutional investors.
NextCure Company Profile
NextCure, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. The company researches immunomedicines designed to influence how immune cells recognize and respond to tumors; it does not market approved commercial products. Its discovery work has included antibody-based and small-molecule candidates aimed at immune-related targets such as Siglec-15, LAIR-1 and CBL-B. NextCure has used its FIND-IT platform to identify and investigate potential therapeutic targets and drug candidates.
Featured Articles
- Five stocks we like better than NextCure
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.
